Kymera Therapeutics - KYMR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $57.86
  • Forecasted Upside: 80.80 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$32.00
▲ +2.91 (10.00%)

This chart shows the closing price for KYMR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kymera Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KYMR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KYMR

Analyst Price Target is $57.86
▲ +80.80% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $57.86, with a high forecast of $85.00 and a low forecast of $26.00. The average price target represents a 80.80% upside from the last price of $32.00.

This chart shows the closing price for KYMR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in Kymera Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/20/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/21/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/20/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022Jefferies Financial GroupInitiated CoverageBuy$40.00Low
8/10/2022Credit Suisse GroupBoost TargetOutperform$60.00 ➝ $61.00Low
8/3/2022The Goldman Sachs GroupInitiated CoverageBuy$40.00Low
7/20/2022SVB LeerinkInitiated CoverageMarket Perform$26.00Low
6/1/2022Wells Fargo & CompanyLower TargetOverweight$62.00 ➝ $35.00High
5/23/2022Piper SandlerLower TargetOverweight$91.00 ➝ $43.00Medium
5/4/2022B. RileyLower Target$67.00 ➝ $50.00High
4/28/2022Credit Suisse GroupInitiated CoverageOutperform$63.00High
3/10/2022JPMorgan Chase & Co.Initiated CoverageNeutral$44.00Medium
3/2/2022Morgan StanleyLower TargetEqual Weight$68.00 ➝ $66.00Medium
2/10/2022Wells Fargo & CompanyInitiated CoverageOverweight$62.00Medium
12/17/2021HC WainwrightReiterated RatingBuy$85.00High
10/13/2021Brookline Capital AcquisitionInitiated CoverageBuy$80.00Low
10/13/2021Brookline Capital ManagementReiterated RatingBuy$80.00Medium
9/30/2021B. RileyInitiated CoverageNeutral$67.00Medium
9/29/2021Stifel NicolausInitiated CoverageBuy$80.00Low
9/10/2021Bank of AmericaDowngradeBuy ➝ Neutral$65.00 ➝ $80.00High
8/18/2021Morgan StanleyLower TargetEqual Weight$69.00 ➝ $68.00High
7/16/2021Morgan StanleyBoost TargetEqual Weight$67.00 ➝ $69.00High
5/20/2021UBS GroupInitiated CoverageBuy$80.00High
5/18/2021Morgan StanleyLower TargetEqual Weight$69.00 ➝ $67.00High
4/14/2021Berenberg BankInitiated CoverageBuyHigh
3/23/2021Morgan StanleyLower TargetEqual Weight$74.00 ➝ $69.00High
1/19/2021Morgan StanleyBoost TargetEqual Weight$45.00 ➝ $74.00High
12/4/2020HC WainwrightInitiated CoverageBuyMedium
11/24/2020Morgan StanleyBoost TargetEqual Weight$27.00 ➝ $45.00High
11/13/2020Piper SandlerInitiated CoverageOverweightLow
9/15/2020Bank of AmericaInitiated CoverageNeutral$35.00High
9/15/2020Morgan StanleyInitiated CoverageEqual Weight$27.00High
9/15/2020GuggenheimInitiated CoverageBuy$42.00High
9/15/2020CowenInitiated CoverageOutperformHigh
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/21/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
3/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/21/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
5/21/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
6/20/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2022
  • 2 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/19/2022

Current Sentiment

  • 2 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $32.00
Low: $28.22
High: $32.37

50 Day Range

MA: $23.41
Low: $14.17
High: $34.05

52 Week Range

Now: $32.00
Low: $13.15
High: $69.12

Volume

1,072,834 shs

Average Volume

603,815 shs

Market Capitalization

$1.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Kymera Therapeutics?

The following Wall Street research analysts have issued stock ratings on Kymera Therapeutics in the last twelve months: B. Riley, Bank of America Co., Brookline Capital Acquisition Corp., Brookline Capital Management, Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for KYMR.

What is the current price target for Kymera Therapeutics?

14 Wall Street analysts have set twelve-month price targets for Kymera Therapeutics in the last year. Their average twelve-month price target is $57.86, suggesting a possible upside of 80.8%. HC Wainwright has the highest price target set, predicting KYMR will reach $85.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $26.00 for Kymera Therapeutics in the next year.
View the latest price targets for KYMR.

What is the current consensus analyst rating for Kymera Therapeutics?

Kymera Therapeutics currently has 5 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KYMR will outperform the market and that investors should add to their positions of Kymera Therapeutics.
View the latest ratings for KYMR.

What other companies compete with Kymera Therapeutics?

How do I contact Kymera Therapeutics' investor relations team?

Kymera Therapeutics' physical mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The company's listed phone number is 857-285-5300 and its investor relations email address is [email protected] The official website for Kymera Therapeutics is www.kymeratx.com. Learn More about contacing Kymera Therapeutics investor relations.